MD3224256T2 - Compuși N-((het)arilmetil)-heteroaril-carboxamidici în calitate de inhibitori ai kalikreinei plasmatice - Google Patents
Compuși N-((het)arilmetil)-heteroaril-carboxamidici în calitate de inhibitori ai kalikreinei plasmaticeInfo
- Publication number
- MD3224256T2 MD3224256T2 MDE20170127T MDE20170127T MD3224256T2 MD 3224256 T2 MD3224256 T2 MD 3224256T2 MD E20170127 T MDE20170127 T MD E20170127T MD E20170127 T MDE20170127 T MD E20170127T MD 3224256 T2 MD3224256 T2 MD 3224256T2
- Authority
- MD
- Moldova
- Prior art keywords
- compounds
- arylmethyl
- het
- heteroaryl
- plasma kallikrein
- Prior art date
Links
- 102000003827 Plasma Kallikrein Human genes 0.000 title abstract 2
- 108090000113 Plasma Kallikrein Proteins 0.000 title abstract 2
- 229940127379 Kallikrein Inhibitors Drugs 0.000 title 1
- 125000005002 aryl methyl group Chemical group 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Aceasta invenţie furnizează compuşi cu formula (I):compoziţiile cuprinzând asemenea compuşi; utilizarea unor astfel de compuşi în terapie (de exemplu în tratamentul sau prevenirea unei boli sau afecţiuni în care este implicată activitatea plasmei kallikrein); şi metode pentru tratatrea pacienţilor cu astfel de compuşi; în care R5, R6, R7, A, B, W, X, Y şi Z sunt cum au fost definiţi aici.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1421083.5A GB201421083D0 (en) | 2014-11-27 | 2014-11-27 | Enzyme inhibitors |
PCT/GB2015/053615 WO2016083820A1 (en) | 2014-11-27 | 2015-11-26 | N-((het)arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors, |
Publications (1)
Publication Number | Publication Date |
---|---|
MD3224256T2 true MD3224256T2 (ro) | 2019-12-31 |
Family
ID=52349552
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MDE20170127T MD3224256T2 (ro) | 2014-11-27 | 2015-11-26 | Compuși N-((het)arilmetil)-heteroaril-carboxamidici în calitate de inhibitori ai kalikreinei plasmatice |
MDE20191295T MD3567037T2 (ro) | 2014-11-27 | 2015-11-26 | Compuși N-((het)arilmetil)-heteroaril-carboxamide în calitate de inhibitori ai kallikreinei plasmatice |
MDE20191218T MD3556752T2 (ro) | 2014-11-27 | 2015-11-26 | Compuși de N-((het)arilmetil)-heteroaril-carboxamide în calitate de inhibitori ai kallikreinei plasmatice |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MDE20191295T MD3567037T2 (ro) | 2014-11-27 | 2015-11-26 | Compuși N-((het)arilmetil)-heteroaril-carboxamide în calitate de inhibitori ai kallikreinei plasmatice |
MDE20191218T MD3556752T2 (ro) | 2014-11-27 | 2015-11-26 | Compuși de N-((het)arilmetil)-heteroaril-carboxamide în calitate de inhibitori ai kallikreinei plasmatice |
Country Status (37)
Country | Link |
---|---|
US (6) | US10364238B2 (ro) |
EP (4) | EP3224256B1 (ro) |
JP (4) | JP6653702B2 (ro) |
KR (2) | KR102496404B1 (ro) |
CN (2) | CN110577519A (ro) |
AR (2) | AR102850A1 (ro) |
AU (2) | AU2015352193B2 (ro) |
BR (1) | BR112017010882B8 (ro) |
CA (1) | CA2967894C (ro) |
CL (1) | CL2017001362A1 (ro) |
CO (1) | CO2017006230A2 (ro) |
CY (3) | CY1122255T1 (ro) |
DK (3) | DK3224256T3 (ro) |
EC (1) | ECSP17039127A (ro) |
ES (3) | ES2908303T3 (ro) |
GB (1) | GB201421083D0 (ro) |
HK (1) | HK1244268A1 (ro) |
HR (3) | HRP20220314T1 (ro) |
HU (3) | HUE053317T2 (ro) |
IL (2) | IL278182B (ro) |
LT (3) | LT3567037T (ro) |
MA (3) | MA41014B1 (ro) |
MD (3) | MD3224256T2 (ro) |
ME (1) | ME03514B (ro) |
MX (2) | MX2017006823A (ro) |
MY (1) | MY176853A (ro) |
NZ (1) | NZ731945A (ro) |
PH (1) | PH12017500901A1 (ro) |
PL (3) | PL3556752T3 (ro) |
PT (3) | PT3224256T (ro) |
RS (3) | RS63155B1 (ro) |
RU (2) | RU2707870C2 (ro) |
SG (2) | SG10201907819WA (ro) |
SI (3) | SI3567037T1 (ro) |
TW (2) | TWI741377B (ro) |
UA (1) | UA123087C2 (ro) |
WO (1) | WO2016083820A1 (ro) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI636047B (zh) | 2013-08-14 | 2018-09-21 | 英商卡爾維斯塔製藥有限公司 | 雜環衍生物 |
GB201421085D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | New enzyme inhibitors |
GB201421083D0 (en) * | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | Enzyme inhibitors |
TWI734702B (zh) | 2015-10-01 | 2021-08-01 | 美商百歐克斯製藥公司 | 人類血漿激肽釋放酶抑制劑 |
GB201609519D0 (en) * | 2016-05-31 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of n-[(2,6-difluoro-3-methoxyphenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyr idin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide |
SI3464271T1 (sl) * | 2016-05-31 | 2020-10-30 | Kalvista Pharmaceuticals Limited | Derivati pirazola kot inhibitorji plazemskega kalikreina |
GB201609607D0 (en) * | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts |
GB201609603D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide |
WO2018200674A1 (en) * | 2017-04-26 | 2018-11-01 | Mitobridge, Inc. | Dynamin-1-like protein inhibitors |
TW201925188A (zh) * | 2017-11-29 | 2019-07-01 | 英商卡爾維斯塔製藥有限公司 | 酶抑制劑 |
DK3716952T3 (da) | 2017-11-29 | 2022-03-14 | Kalvista Pharmaceuticals Ltd | Doseringsformer omfattende en plasmakallikrein-inhibitor |
GB201721515D0 (en) * | 2017-12-21 | 2018-02-07 | Kalvista Pharmaceuticals Ltd | Dosage forms comprising a plasma kallikrein inhibtor |
GB201719881D0 (en) | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of plasma kallikrein inhibitor and salts thereof |
GB201719882D0 (en) * | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of a plasma kallikrein inhibitor and salts thereof |
EP3765459A1 (en) | 2018-03-13 | 2021-01-20 | Shire Human Genetic Therapies, Inc. | Substituted imidazopyridines as inhibitors of plasma kallikrein and uses thereof |
US11034669B2 (en) | 2018-11-30 | 2021-06-15 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
GB201910116D0 (en) | 2019-07-15 | 2019-08-28 | Kalvista Pharmaceuticals Ltd | Treatments of hereditary angioedema |
GB201910125D0 (en) * | 2019-07-15 | 2019-08-28 | Kalvista Pharmaceuticals Ltd | Treatments of angioedema |
EP4010333A1 (en) | 2019-08-09 | 2022-06-15 | Kalvista Pharmaceuticals Limited | Plasma kallikrein inhibitors |
CN114728962A (zh) | 2019-09-18 | 2022-07-08 | 武田药品工业有限公司 | 血浆激肽释放酶抑制剂及其用途 |
WO2021055589A1 (en) | 2019-09-18 | 2021-03-25 | Shire Human Genetic Therapies, Inc. | Heteroaryl plasma kallikrein inhibitors |
WO2021121396A1 (zh) * | 2019-12-20 | 2021-06-24 | 成都康弘药业集团股份有限公司 | 作为血浆激肽释放酶抑制剂的三环类化合物及其用途 |
TW202144331A (zh) * | 2020-02-13 | 2021-12-01 | 德商百靈佳殷格翰國際股份有限公司 | 作為血漿激肽釋放酶抑制劑之雜芳族甲醯胺衍生物 |
WO2021175290A1 (zh) * | 2020-03-04 | 2021-09-10 | 南京明德新药研发有限公司 | 杂环类化合物 |
TW202228686A (zh) | 2020-10-15 | 2022-08-01 | 英商卡爾維斯塔製藥有限公司 | 血管性水腫之治療 |
EP4232031A1 (en) | 2020-10-23 | 2023-08-30 | Kalvista Pharmaceuticals Limited | Treatments of angioedema |
JP2024505596A (ja) | 2021-02-09 | 2024-02-06 | カルビスタ・ファーマシューティカルズ・リミテッド | 遺伝性血管性浮腫の治療 |
WO2023002219A1 (en) | 2021-07-23 | 2023-01-26 | Kalvista Pharmaceuticals Limited | Treatments of hereditary angioedema |
WO2023185634A1 (zh) * | 2022-03-30 | 2023-10-05 | 南京明德新药研发有限公司 | 作为血浆激肽释放酶抑制剂的杂环类化合物 |
EP4288036A1 (en) | 2022-04-27 | 2023-12-13 | Kalvista Pharmaceuticals Limited | Formulations of a plasma kallikrein inhibitor |
WO2024025907A1 (en) * | 2022-07-29 | 2024-02-01 | Rezolute, Inc. | Inhibitors of plasma kallikrein |
Family Cites Families (98)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5187157A (en) | 1987-06-05 | 1993-02-16 | Du Pont Merck Pharmaceutical Company | Peptide boronic acid inhibitors of trypsin-like proteases |
GB9019558D0 (en) | 1990-09-07 | 1990-10-24 | Szelke Michael | Enzyme inhibitors |
SE9301911D0 (sv) | 1993-06-03 | 1993-06-03 | Ab Astra | New peptide derivatives |
US5589467A (en) | 1993-09-17 | 1996-12-31 | Novo Nordisk A/S | 2,5',N6-trisubstituted adenosine derivatives |
US5786328A (en) | 1995-06-05 | 1998-07-28 | Genentech, Inc. | Use of kunitz type plasma kallikrein inhibitors |
US7101878B1 (en) | 1998-08-20 | 2006-09-05 | Agouron Pharmaceuticals, Inc. | Non-peptide GNRH agents, methods and intermediates for their preparation |
IL144910A0 (en) * | 1999-04-15 | 2002-06-30 | Bristol Myers Squibb Co | Cyclic compounds and pharmaceutical compositions containing the same |
DE60218511T2 (de) | 2001-10-26 | 2007-10-25 | Istituto Di Richerche Di Biologia Molecolare P. Angeletti S.P.A. | Dihydroxypyrimidin-carbonsäueramid-hemmer der hiv-integrase |
EP1451160B1 (en) | 2001-11-01 | 2010-01-13 | Icagen, Inc. | Pyrazole-amides for use in the treatment of pain |
GB0205527D0 (en) | 2002-03-08 | 2002-04-24 | Ferring Bv | Inhibitors |
ES2298513T3 (es) | 2002-04-26 | 2008-05-16 | Eli Lilly And Company | Derivados de tiazol como antagonistas del receptor de taquicinina. |
EP1426364A1 (en) | 2002-12-04 | 2004-06-09 | Aventis Pharma Deutschland GmbH | Imidazole-derivatives as factor Xa inhibitors |
DE10301300B4 (de) | 2003-01-15 | 2009-07-16 | Curacyte Chemistry Gmbh | Verwendung von acylierten 4-Amidino- und 4-Guanidinobenzylaminen zur Inhibierung von Plasmakallikrein |
TW200505450A (en) | 2003-02-03 | 2005-02-16 | Janssen Pharmaceutica Nv | Quinoline-derived amide modulators of vanilloid VR1 receptor |
JP4951339B2 (ja) | 2003-08-27 | 2012-06-13 | オプソテツク・コーポレイシヨン | 眼血管新生疾患の治療のための併用療法 |
TW200526588A (en) * | 2003-11-17 | 2005-08-16 | Smithkline Beecham Corp | Chemical compounds |
GB0403155D0 (en) | 2004-02-12 | 2004-03-17 | Vernalis Res Ltd | Chemical compounds |
EP1568698A1 (en) | 2004-02-27 | 2005-08-31 | Aventis Pharma Deutschland GmbH | Pyrrole-derivatives as factor Xa inhibitors |
US7429604B2 (en) | 2004-06-15 | 2008-09-30 | Bristol Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
BRPI0514843A (pt) | 2004-09-03 | 2008-06-24 | Yuhan Corp | derivados de pirrolo[3,2-c] piridina e processos para a preparação dos mesmos |
EP2500031A3 (en) | 2005-02-24 | 2012-12-26 | Joslin Diabetes Center, Inc. | Compositions and Methods for Treating Vascular Permeability |
GB0508472D0 (en) | 2005-04-26 | 2005-06-01 | Glaxo Group Ltd | Compounds |
KR101142363B1 (ko) | 2005-06-27 | 2012-05-21 | 주식회사유한양행 | 피롤로피리딘 유도체를 포함하는 항암제 조성물 |
WO2007011328A1 (en) | 2005-07-14 | 2007-01-25 | Jackson Kenneth A | A method for disabling a hypodermic needle after use |
AU2006270322A1 (en) | 2005-07-14 | 2007-01-25 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
US20070254894A1 (en) | 2006-01-10 | 2007-11-01 | Kane John L Jr | Novel small molecules with selective cytotoxicity against human microvascular endothelial cell proliferation |
GB0606876D0 (en) * | 2006-04-05 | 2006-05-17 | Glaxo Group Ltd | Compounds |
US20070258976A1 (en) | 2006-05-04 | 2007-11-08 | Ward Keith W | Combination Therapy for Diseases Involving Angiogenesis |
SI2049478T1 (sl) | 2006-07-06 | 2012-08-31 | Glaxo Group Ltd | Substituirani N-fenilmetil-5-okso-prolin-2-amidi kot antagonisti receptorja P2X7 in postopki za njihovo uporabo |
CA2658523C (en) | 2006-07-31 | 2012-06-12 | Activesite Pharmaceuticals, Inc. | Inhibitors of plasma kallikrein |
DE102006050672A1 (de) | 2006-10-24 | 2008-04-30 | Curacyte Discovery Gmbh | Hemmstoffe des Plasmins und des Plasmakallikreins |
BRPI0721298A2 (pt) | 2006-12-29 | 2014-03-25 | Abbott Gmbh & Co Kg | Composto de carboxamida e seus usos como inibidores de calpaína |
US20100119512A1 (en) | 2007-01-25 | 2010-05-13 | Joslin Diabetes Center | Methods of diagnosing, treating, and preventing increased vascular permeability |
US20080221093A1 (en) | 2007-03-07 | 2008-09-11 | Christian Gege | Metalloprotease inhibitors containing a heterocyclic moiety |
MX2009009443A (es) | 2007-03-30 | 2009-09-14 | Sanofi Aventis | Compuestos de pirimidina hidrazida como inhibidores de pgds. |
JP2010523524A (ja) | 2007-04-03 | 2010-07-15 | グラクソ グループ リミテッド | P2x7調節因子としてのイミダゾリジンカルボキサミド誘導体 |
RU2010106393A (ru) | 2007-07-26 | 2011-09-10 | Зингента Партисипейшнс Аг (Ch) | Новые микробиоциды |
JP2010536871A (ja) | 2007-08-22 | 2010-12-02 | アラーガン、インコーポレイテッド | スフィンゴシン−1−リン酸受容体アゴニストまたはアンタゴニスト生物学的活性を有するピロール化合物 |
AU2008345225A1 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
WO2009083553A1 (en) | 2007-12-31 | 2009-07-09 | Rheoscience A/S | Azine compounds as glucokinase activators |
US8658685B2 (en) | 2008-01-31 | 2014-02-25 | Activesite Pharmaceuticals, Inc. | Methods for treatment of kallikrein-related disorders |
WO2009106980A2 (en) | 2008-02-29 | 2009-09-03 | Pfizer Inc. | Indazole derivatives |
JP5537442B2 (ja) | 2008-03-13 | 2014-07-02 | ブリストル−マイヤーズ スクイブ カンパニー | 第xia因子阻害剤としてのピリダジン誘導体 |
CN102149680B (zh) | 2008-07-08 | 2014-12-10 | 第一三共株式会社 | 含氮芳族杂环化合物 |
US8324385B2 (en) | 2008-10-30 | 2012-12-04 | Madrigal Pharmaceuticals, Inc. | Diacylglycerol acyltransferase inhibitors |
GB0910003D0 (en) | 2009-06-11 | 2009-07-22 | Univ Leuven Kath | Novel compounds for the treatment of neurodegenerative diseases |
MX2012006913A (es) | 2009-12-18 | 2012-08-23 | Activesite Pharmaceuticals Inc | Profarmacos de inhibidores de calicreina plasmatica. |
JP2011157349A (ja) | 2010-01-07 | 2011-08-18 | Daiichi Sankyo Co Ltd | 含窒素芳香族ヘテロシクリル化合物を含有する医薬組成物 |
ES2569983T3 (es) | 2010-01-28 | 2016-05-13 | The Medicines Company (Leipzig) Gmbh | Inhibidores de serinproteasa de tipo tripsina y su preparación y uso |
JP2013121919A (ja) | 2010-03-25 | 2013-06-20 | Astellas Pharma Inc | 血漿カリクレイン阻害剤 |
ES2483802T3 (es) | 2010-07-07 | 2014-08-07 | The Medicines Company (Leipzig) Gmbh | Inhibidores de serina proteasa |
EP2595986A2 (en) | 2010-07-14 | 2013-05-29 | Addex Pharma SA | Novel 2-amino-4-pyrazolyl-thiazole derivatives and their use as allosteric modulators of metabotropic glutamate receptors |
US9290485B2 (en) * | 2010-08-04 | 2016-03-22 | Novartis Ag | N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides |
EP2458315B1 (de) | 2010-11-25 | 2017-01-04 | Balcke-Dürr GmbH | Regenerativer Wärmetauscher mit zwangsgeführter Rotordichtung |
WO2012142308A1 (en) | 2011-04-13 | 2012-10-18 | Activesite Pharmaceuticals, Inc. | Prodrugs of inhibitors of plasma kallikrein |
US9133128B2 (en) | 2011-06-17 | 2015-09-15 | Research Triangle Institute | Pyrazole derivatives as cannabinoid receptor 1 antagonists |
GB2494851A (en) | 2011-07-07 | 2013-03-27 | Kalvista Pharmaceuticals Ltd | Plasma kallikrein inhibitors |
US8952180B2 (en) | 2011-09-27 | 2015-02-10 | Bristol-Myers Squibb Company | Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors |
US9249096B2 (en) | 2011-09-27 | 2016-02-02 | Bristol-Myers Squibb Company | Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors |
WO2013111108A1 (en) * | 2012-01-27 | 2013-08-01 | Novartis Ag | 5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors |
EP2807156A1 (en) | 2012-01-27 | 2014-12-03 | Novartis AG | Aminopyridine derivatives as plasma kallikrein inhibitors |
AU2013216721B2 (en) | 2012-02-10 | 2017-09-28 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
WO2013130603A1 (en) | 2012-02-27 | 2013-09-06 | Board Of Regents, The University Of Texas System | Ganglioside gd2 as a marker and target on cancer stem cells |
GB201212081D0 (en) | 2012-07-06 | 2012-08-22 | Kalvista Pharmaceuticals Ltd | New polymorph |
CN104918942A (zh) | 2013-01-08 | 2015-09-16 | 萨维拉制药有限公司 | 嘧啶酮衍生物和它们用于治疗、改善或预防病毒疾病的用途 |
GB201300304D0 (en) * | 2013-01-08 | 2013-02-20 | Kalvista Pharmaceuticals Ltd | Benzylamine derivatives |
GB2510407A (en) | 2013-02-04 | 2014-08-06 | Kalvista Pharmaceuticals Ltd | Aqueous suspensions of kallikrein inhibitors for parenteral administration |
CA2897336C (en) | 2013-01-20 | 2023-10-17 | Dyax Corp. | Evaluation and treatment of pkal-mediated disorders |
EP2968297B1 (en) | 2013-03-15 | 2018-09-26 | Verseon Corporation | Multisubstituted aromatic compounds as serine protease inhibitors |
AU2014270152B9 (en) | 2013-05-23 | 2018-03-08 | Kalvista Pharmaceuticals Limited | Heterocyclic derivates |
GB2517908A (en) | 2013-08-14 | 2015-03-11 | Kalvista Pharmaceuticals Ltd | Bicyclic inhibitors |
CA2920815C (en) | 2013-08-14 | 2021-09-21 | Kalvista Pharmaceuticals Limited | Inhibitors of plasma kallikrein |
US9611252B2 (en) | 2013-12-30 | 2017-04-04 | Lifesci Pharmaceuticals, Inc. | Therapeutic inhibitory compounds |
CN106061480B (zh) | 2013-12-30 | 2020-02-28 | 莱福斯希医药公司 | 治疗性抑制性化合物 |
LT3828173T (lt) | 2014-03-07 | 2022-11-10 | Biocryst Pharmaceuticals, Inc. | Pakeistieji pirazolai kaip žmogaus plazmos kalikreino inhibitoriai |
WO2015171526A2 (en) | 2014-05-05 | 2015-11-12 | Global Blood Therapeutics, Inc. | Tricyclic pyrazolopyridine compounds |
WO2015171527A1 (en) | 2014-05-05 | 2015-11-12 | Global Blood Therapeutics, Inc. | Pyrazolopyridine pyrazolopyrimidine and related compounds |
BR112017000816A2 (pt) | 2014-07-16 | 2017-12-05 | Lifesci Pharmaceuticals Inc | compostos inibitórios terapêuticos |
WO2016029214A1 (en) | 2014-08-22 | 2016-02-25 | Biocryst Pharmaceuticals, Inc. | Compositions and uses of amidine derivatives |
JP2017528486A (ja) | 2014-09-17 | 2017-09-28 | ヴァーセオン コーポレイション | セリンプロテアーゼ阻害剤としてのピラゾリル置換ピリドン化合物 |
GB201421085D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | New enzyme inhibitors |
GB201421088D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | New enzyme inhibitors |
GB201421083D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | Enzyme inhibitors |
HUE060104T2 (hu) | 2015-02-27 | 2023-01-28 | Verseon Int Corporation | Szubsztituált pirazol vegyületek mint szerinproteázinhibitorok |
EP3317241A4 (en) | 2015-07-01 | 2019-01-23 | Lifesci Pharmaceuticals, Inc. | THERAPEUTIC INHIBITOR COMPOUNDS |
EP3317259A4 (en) | 2015-07-01 | 2019-06-12 | Lifesci Pharmaceuticals, Inc. | THERAPEUTIC INHIBITING COMPOUNDS |
EP3368529B1 (en) | 2015-10-27 | 2022-04-06 | Boehringer Ingelheim International GmbH | Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors |
US10640486B2 (en) | 2015-10-27 | 2020-05-05 | Boehringer Ingelheim International Gmbh | Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors |
GB201609519D0 (en) | 2016-05-31 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of n-[(2,6-difluoro-3-methoxyphenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyr idin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide |
SI3464271T1 (sl) | 2016-05-31 | 2020-10-30 | Kalvista Pharmaceuticals Limited | Derivati pirazola kot inhibitorji plazemskega kalikreina |
GB201609607D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts |
GB201609603D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide |
GB201609602D0 (en) | 2016-06-01 | 2016-07-13 | Nucuna Biomed Ltd | Chemical compounds |
GB201609601D0 (en) | 2016-06-01 | 2016-07-13 | Nucana Biomed Ltd | Phosphoramidate compounds |
WO2018011628A1 (en) | 2016-07-11 | 2018-01-18 | Lifesci Pharmaceuticals, Inc. | Therapeutic inhibitory compounds |
GB201719882D0 (en) | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of a plasma kallikrein inhibitor and salts thereof |
TW201925188A (zh) | 2017-11-29 | 2019-07-01 | 英商卡爾維斯塔製藥有限公司 | 酶抑制劑 |
GB201719881D0 (en) | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of plasma kallikrein inhibitor and salts thereof |
-
2014
- 2014-11-27 GB GBGB1421083.5A patent/GB201421083D0/en not_active Ceased
-
2015
- 2015-11-26 RU RU2017122364A patent/RU2707870C2/ru active
- 2015-11-26 ME MEP-2019-234A patent/ME03514B/me unknown
- 2015-11-26 CN CN201910782520.5A patent/CN110577519A/zh active Pending
- 2015-11-26 LT LTEP19182383.0T patent/LT3567037T/lt unknown
- 2015-11-26 NZ NZ731945A patent/NZ731945A/en unknown
- 2015-11-26 PT PT15804210T patent/PT3224256T/pt unknown
- 2015-11-26 MD MDE20170127T patent/MD3224256T2/ro unknown
- 2015-11-26 SI SI201531527T patent/SI3567037T1/sl unknown
- 2015-11-26 SI SI201530836T patent/SI3224256T1/sl unknown
- 2015-11-26 MA MA41014A patent/MA41014B1/fr unknown
- 2015-11-26 HU HUE19182383A patent/HUE053317T2/hu unknown
- 2015-11-26 HU HUE15804210A patent/HUE047425T2/hu unknown
- 2015-11-26 WO PCT/GB2015/053615 patent/WO2016083820A1/en active Application Filing
- 2015-11-26 PT PT191766104T patent/PT3556752T/pt unknown
- 2015-11-26 LT LTEP15804210.1T patent/LT3224256T/lt unknown
- 2015-11-26 KR KR1020217018472A patent/KR102496404B1/ko active IP Right Grant
- 2015-11-26 DK DK15804210.1T patent/DK3224256T3/da active
- 2015-11-26 EP EP15804210.1A patent/EP3224256B1/en active Active
- 2015-11-26 EP EP21215491.8A patent/EP4039681A1/en active Pending
- 2015-11-26 HR HRP20220314TT patent/HRP20220314T1/hr unknown
- 2015-11-26 PL PL19176610T patent/PL3556752T3/pl unknown
- 2015-11-26 EP EP19176610.4A patent/EP3556752B1/en active Active
- 2015-11-26 EP EP19182383.0A patent/EP3567037B1/en active Active
- 2015-11-26 MX MX2017006823A patent/MX2017006823A/es unknown
- 2015-11-26 ES ES19176610T patent/ES2908303T3/es active Active
- 2015-11-26 DK DK19176610.4T patent/DK3556752T3/da active
- 2015-11-26 ES ES15804210T patent/ES2745815T3/es active Active
- 2015-11-26 US US15/527,923 patent/US10364238B2/en active Active
- 2015-11-26 IL IL278182A patent/IL278182B/en unknown
- 2015-11-26 RS RS20220301A patent/RS63155B1/sr unknown
- 2015-11-26 MY MYPI2017701845A patent/MY176853A/en unknown
- 2015-11-26 AU AU2015352193A patent/AU2015352193B2/en active Active
- 2015-11-26 PL PL15804210T patent/PL3224256T3/pl unknown
- 2015-11-26 MD MDE20191295T patent/MD3567037T2/ro unknown
- 2015-11-26 JP JP2017527570A patent/JP6653702B2/ja active Active
- 2015-11-26 PT PT191823830T patent/PT3567037T/pt unknown
- 2015-11-26 RU RU2019131174A patent/RU2019131174A/ru unknown
- 2015-11-26 SG SG10201907819WA patent/SG10201907819WA/en unknown
- 2015-11-26 MX MX2020013038A patent/MX2020013038A/es unknown
- 2015-11-26 RS RSP20191116 patent/RS59395B1/sr unknown
- 2015-11-26 KR KR1020177017538A patent/KR102267623B1/ko active IP Right Grant
- 2015-11-26 RS RS20210205A patent/RS61497B1/sr unknown
- 2015-11-26 BR BR112017010882A patent/BR112017010882B8/pt active IP Right Grant
- 2015-11-26 PL PL19182383T patent/PL3567037T3/pl unknown
- 2015-11-26 SI SI201531813T patent/SI3556752T1/sl unknown
- 2015-11-26 MA MA52063A patent/MA52063B1/fr unknown
- 2015-11-26 CA CA2967894A patent/CA2967894C/en active Active
- 2015-11-26 CN CN201580071671.XA patent/CN107108576B/zh active Active
- 2015-11-26 MA MA47217A patent/MA47217B1/fr unknown
- 2015-11-26 UA UAA201706473A patent/UA123087C2/uk unknown
- 2015-11-26 ES ES19182383T patent/ES2858082T3/es active Active
- 2015-11-26 SG SG11201703988PA patent/SG11201703988PA/en unknown
- 2015-11-26 HU HUE19176610A patent/HUE057647T2/hu unknown
- 2015-11-26 LT LTEP19176610.4T patent/LT3556752T/lt unknown
- 2015-11-26 AR ARP150103900A patent/AR102850A1/es unknown
- 2015-11-26 DK DK19182383.0T patent/DK3567037T3/da active
- 2015-11-26 MD MDE20191218T patent/MD3556752T2/ro unknown
- 2015-11-27 TW TW108135558A patent/TWI741377B/zh active
- 2015-11-27 TW TW104139776A patent/TWI686383B/zh active
-
2017
- 2017-05-15 IL IL252287A patent/IL252287B/en active IP Right Grant
- 2017-05-15 PH PH12017500901A patent/PH12017500901A1/en unknown
- 2017-05-26 CL CL2017001362A patent/CL2017001362A1/es unknown
- 2017-06-22 EC ECIEPI201739127A patent/ECSP17039127A/es unknown
- 2017-06-23 CO CONC2017/0006230A patent/CO2017006230A2/es unknown
-
2018
- 2018-03-15 HK HK18103626.6A patent/HK1244268A1/zh unknown
-
2019
- 2019-06-11 US US16/438,061 patent/US11001578B2/en active Active
- 2019-07-02 US US16/460,630 patent/US10611758B2/en active Active
- 2019-08-23 HR HRP20191524 patent/HRP20191524T1/hr unknown
- 2019-09-30 CY CY20191101020T patent/CY1122255T1/el unknown
- 2019-10-02 AU AU2019240616A patent/AU2019240616B2/en active Active
- 2019-10-08 JP JP2019184938A patent/JP6995101B2/ja active Active
-
2020
- 2020-02-28 US US16/804,872 patent/US11198691B2/en active Active
- 2020-07-31 US US16/944,658 patent/US11084809B2/en active Active
-
2021
- 2021-02-04 AR ARP210100300A patent/AR121273A2/es active IP Right Grant
- 2021-03-01 HR HRP20210350TT patent/HRP20210350T1/hr unknown
- 2021-03-08 CY CY20211100194T patent/CY1124046T1/el unknown
- 2021-07-28 JP JP2021123024A patent/JP7148683B2/ja active Active
- 2021-10-20 US US17/506,261 patent/US20220289729A1/en not_active Abandoned
-
2022
- 2022-03-11 CY CY20221100202T patent/CY1125214T1/el unknown
- 2022-09-21 JP JP2022149897A patent/JP2022180520A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MD3224256T2 (ro) | Compuși N-((het)arilmetil)-heteroaril-carboxamidici în calitate de inhibitori ai kalikreinei plasmatice | |
MD3464271T2 (ro) | Derivați de pirazol în calitate de inhibitori ai kaliсreinei plasmatice | |
PH12015502549B1 (en) | Heterocyclic derivatives | |
MD3472167T2 (ro) | Compuși heterociclici ca imunomodulatori | |
MX366498B (es) | Inhibidores de calicreina plasmatica. | |
MD3377488T2 (ro) | Compuși heterociclici ca imunomodulatori | |
MX2019007256A (es) | Inhibidores de las fosfodiesterasas y métodos de tratamiento microbiano. | |
NZ709609A (en) | Benzylamine derivatives | |
MD3319611T2 (ro) | Oxisteroli și metode de utilizare a acestora | |
EA201690979A1 (ru) | Производные азепана и способы лечения инфекций гепатита в | |
MD3319612T2 (ro) | Oxisteroli și metode de utilizare a acestora | |
MX2016008688A (es) | Compuestos terapéuticos inhibidores. | |
MX2017012545A (es) | Compuestos heterociclicos y su uso en la prevencion o tratamiento de las infecciones bacterianas. | |
BR112017026061A2 (pt) | composto, uso de um composto, e, método de tratamento de uma infecção viral | |
MX2016009248A (es) | Compuestos que contienen nitrogeno y su uso como agentes antibacterianos. | |
EA201692358A1 (ru) | Производные изоиндолина для применения в лечении вирусной инфекции | |
MX2019015212A (es) | Compuestos para el tratamiento del sarcoma. | |
MD3355890T2 (ro) | Inhibitori de kalikreină plasmatică umană | |
MX2017012535A (es) | Compuestos hetorociclicos novedosos y su uso en la prevencion o tratamiento de las infecciones bacterianas. | |
MX2017014080A (es) | Compuestos heterociclicos y su uso en la prevencion o tratamiento de las infecciones bacterianas. | |
MX2022000545A (es) | Inhibidores de enzimas. | |
MX2017012539A (es) | Compuestos heterociclicos y su uso en la prevencion o tratamiento de las infecciones bacterianas. | |
EA201992234A1 (ru) | Средство для профилактики миопии, лечения миопии и/или предотвращения прогрессирования миопии, включающее тиотропий в качестве активного ингредиента | |
SG10201903630UA (en) | Iminosugars useful for the treatment of viral diseases | |
MX2015016167A (es) | Tratamiento de la vasculopatia coroidea polipoidal. |